{"id":"f46e6824-c41c-4451-af0e-b80672c36f6f","arxiv_id":"2412.07050","paper_version":1,"verdict":"REJECT","confidence":"MODERATE","novelty_score":1.0,"correctness_risk":"high","formal_verification":"none","parameter_count":0,"one_line_summary":"This paper is a narrative review asserting that CNN, RNN, and transformer models can improve clinical trial recruitment, monitoring, and personalized medicine, but it reports no verifiable experiments, data, or code.","lead":"This paper surveys how deep learning and predictive models could improve clinical trials, reporting model accuracies and cost reductions. It provides no code, dataset, or experimental evidence for these numbers, so the specific results cannot be verified.","discovery_kind":"review","skeptic_critique":{"model":"deepseek-v4-flash","headline":"The claimed CNN/RNN/transformer results rest on an unverifiable custom dataset: no code or data are released, and Table 1's 1000 Genomes count does not match that project's 2,504 public samples.","rationale":"The reader's weakest assumption—that the custom dataset exists, was assembled as described, and generated the reported numbers—is exactly the load-bearing condition. My pass adds two concrete correctness concerns rather than a new objection: (1) the synthetic-data share is never quantified, so the test-set metrics in Section 4 may not measure real clinical data; and (2) Table 1's 1000 Genomes count is hard to reconcile with the public sample size, which undermines confidence in the dataset description even before considering the absence of artifacts. I agree with the REJECT verdict: a paper that presents original accuracy/AUC/F1 results and operational impact percentages without data, code, or a precise data dictionary cannot support those claims. The paper is clearly organized and the literature-review portions are readable, but independent support is absent: there is no formal verification, no released reproducibility package, and no external validation. The proposed test is the minimal check that would settle the concern, and it is feasible if the dataset is real. No change to the reader's verdict is needed.","tokens_in":16166,"tokens_out":4911,"duration_ms":51032,"concrete_test":"Require the authors to release the de-identified dataset (or a documented access procedure) and training code, then independently reproduce the CNN row of Table 4 on the described MIMIC-III subset. If the 1000 Genomes contribution cannot be reconciled with the cited public resource, or the retrained CNN does not reproduce 92% accuracy and 0.96 ROC-AUC, the central empirical claim fails.","verdict_should_be":"UNCHANGED","load_bearing_attack":"The load-bearing assertion is that a 110,000-record multimodal dataset from MIMIC-III, 1000 Genomes, government surveys, and open clinical text was used to train the models in Section 3.5 and produce the Section 4 metrics (CNN 92% accuracy/0.96 ROC-AUC, RNN 88% F1, transformer 93% precision) and the operational claims (25% faster recruitment, 30% lower cost). Every reported number depends on this dataset existing, being assembled as described, and being split into train/validation/test without leakage. That condition is currently unsupported and partly contradicted by the text. Section 3.2 says synthetic GAN data were added, but Section 4 never states what fraction of the test set is synthetic; if the reported accuracy/AUC come from generated records, the clinical interpretation is invalid. Table 1 lists 10,000 'genomic records' from the 1000 Genomes Project, whose public release contains 2,504 individuals; unless 'records' means something else, the table is inconsistent with the cited source. No code repository, data dictionary, hyperparameters, split sizes, or raw result tables are provided, so the metrics cannot be checked. This is a correctness risk, not merely a style or reproducibility preference.","agreement_with_reader":"agree"},"referee_report":{"model":"deepseek-v4-flash","summary":"The paper claims to train and evaluate CNN, RNN/LSTM, and transformer/BERT models on a custom multimodal clinical dataset, reporting high accuracy (CNN 92%), ROC-AUC (0.96), F1 (RNN 88%), precision (transformer 93%), and operational gains such as 25% faster recruitment and 30% lower costs. It also presents use cases for patient stratification, adverse event prediction, and personalized medicine. The manuscript describes data sources, preprocessing, model architectures, and an experimental setup, but provides no dataset, code, hyperparameter details, split sizes, baseline comparisons, or raw result tables. Every reported metric and operational claim depends on an unverifiable custom dataset described in Section 3.2 and Table 1.","tokens_in":16442,"tokens_out":2364,"duration_ms":25830,"significance":"If the reported results were substantiated, the paper could offer a useful demonstration of deep learning applied to clinical trial workflows, and the proposed framework of integrating imaging, temporal, and text data is a plausible direction. However, the contribution is currently not assessable: there is no reproducible experiment, no dataset release, no code, no statistical uncertainty quantification, and no comparison against established baselines. The paper also does not provide a machine-checked derivation or any verifiable artifact. The central empirical claims are therefore unsupported, and the scientific value cannot be confirmed from the manuscript as submitted.","major_comments":[{"comment":"The entire experimental section depends on a custom dataset described in Section 3.2 and Table 1, but the dataset is not available and its description is internally inconsistent. Table 1 lists 10,000 'genomic records' from the 1000 Genomes Project, yet the public release of that project contains 2,504 individuals; the manuscript does not define what a 'record' means here, and no accession or processing details are given. Similarly, the 50,000 MIMIC-III records, 30,000 demographics records, and 20,000 text records are asserted without a data dictionary, inclusion/exclusion operationalization, or evidence that these data were actually assembled and merged. Because every metric in Section 4 is derived from this dataset, the reported results are unverifiable.","section":"Section 3.2, Table 1"},{"comment":"The manuscript states that synthetic GAN-generated data were added to augment real-world data, but Section 4 does not state what fraction of the test set is synthetic or whether the reported accuracy, precision, recall, and ROC-AUC values were computed on real, synthetic, or mixed records. If the metrics are partly or wholly based on generated data, the clinical interpretation of the results is invalid. The paper must either report separate results on real and synthetic test sets or justify why synthetic data are valid for clinical evaluation. This missing information is load-bearing for the central claim that the models achieve the reported performance.","section":"Section 3.2 and Section 4.1.1"},{"comment":"The model performance numbers (CNN 92% accuracy, 0.96 ROC-AUC; RNN 88% F1; transformer 93% precision) are presented as experimental results, but the paper provides no training details, no hyperparameter values, no exact train/validation/test split sizes, no confidence intervals or error bars, and no baseline comparisons to standard methods. In particular, Section 3.6.1 states a 70/15/15 split but does not report the actual number of samples in each set, and no classifier comparison is made to logistic regression, random forests, or other standard approaches. As written, the numbers in Table 4 are narrative assertions rather than reproducible measurements.","section":"Section 4.1.1 and Table 4"},{"comment":"The operational claims — 25% reduction in recruitment time, 30% reduction in manual data processing costs, up to $500,000 savings per trial, and trial success rates of 80% for transformers versus 65% for RNNs and 60% for traditional methods — are not tied to any experiment, simulation, or statistical analysis described in the methodology. No data, model, or procedure is provided for how these percentages were obtained, and the cited references do not support these specific numbers. These claims are load-bearing for the paper's conclusion that deep learning materially improves clinical trial workflows, yet they are unsupported.","section":"Section 4.1.3 and Figure 9"},{"comment":"The case studies in Section 3.7 — for example, 85% glioblastoma stratification accuracy, 92% cardiotoxicity prediction accuracy, and a 20% reduction in hypoglycemic episodes — are introduced with 'Example:' and appear to be illustrative, but the Results section then presents similar numbers as experimental outcomes without clarifying which values are measured and which are illustrative. This conflation makes it impossible to determine which results were actually obtained by the authors versus which are hypothetical or borrowed from other studies. The manuscript must clearly distinguish measured results from illustrative scenarios, and it must provide supporting data for any measured result.","section":"Section 3.7 and Section 4"}],"minor_comments":[{"comment":"The copyright line contains a typo: 'Liscense' should be 'License'.","section":"Title page"},{"comment":"Reference [15] and reference [51] both list 'Attention is all you need' with the same authors, and reference [51] is malformed; this duplicate should be consolidated and properly formatted.","section":"References [15] and [51]"},{"comment":"The caption 'Visualization of Case studies with visualizations of stratified patient groups' is redundant; it should be simplified, for example to 'Visualization of stratified patient groups using t-SNE plots.'","section":"Figure 4 caption"},{"comment":"The text says 'PyTorch:' with a trailing colon instead of a period, and the formatting of the tool list is inconsistent; this should be corrected for readability.","section":"Section 3.5.4"},{"comment":"Several references are unrelated to the statements they are attached to, such as reference [7] on sustainable packaging attached to a claim about IBM Watson for Clinical Trials, and references [19]–[21] attached to data preprocessing claims; the authors should revise the citation list so that each claim is supported by a relevant source.","section":"References"}],"recommendation":"reject","confidential_remarks":"The paper's central empirical claims are not verifiable from the manuscript: the custom dataset is not released, the numbers appear to be narrative assertions, and several references do not support the claims they are attached to. The reference list also contains a notable number of self-citations and apparently unrelated works, which raises concerns about citation diligence. In addition, the manuscript's presentation as a research article in a machine learning context is questionable given the absence of any reproducible experimental artifact; the fit with the journal's standards for empirical research is poor. I would recommend rejection, although the authors could in principle resubmit if they provide the dataset, code, full experimental details, and a clear separation of measured results from illustrative examples."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"Short version: don't send this to review as a research paper. It is a competent-looking survey of deep learning for clinical trials with a set of headline numbers (CNN 92% accuracy, RNN 88% F1, transformer 93% precision, 25% faster recruitment, 30% lower cost) that are presented as measured results but have no artifact behind them. The only claimed novelty—the custom dataset and integration framework—is unsubstantiated. The reader's reject verdict is right, and the stress-test note adds a concrete inconsistency: Table 1 says 10,000 genomic records from 1000 Genomes, whose public release has 2,504 samples. Unless 'records' means something else, that table does not match the cited source.\n\nWhat is actually good: the organization is clear, and someone unfamiliar with the area could get a reasonable map of CNNs for imaging, RNNs/LSTMs for time series, transformers for text, survival analysis, and common use cases. The limitations section acknowledges interpretability, bias, privacy, and compute. That is real credit, though it is textbook-level.\n\nWhere it falls apart: the empirical core. Section 3 describes a custom 110,000-record multimodal dataset and Section 4 reports per-model metrics and operational improvements, but there is no dataset release, no code, no training details, no hyperparameters, no split sizes, no raw result tables, and no external validation. The reader is asked to take the numbers on faith. The GAN-synthetic data makes it worse: Section 3.2 says synthetic data were added, but Section 4 never states what fraction of the test set is synthetic, so the clinical interpretation of the accuracy/AUC is unclear even if the dataset existed. Citation practice is also weak; several references (sustainable packaging, tax frameworks, MATLAB loop execution) do not support the sentences they are attached to. That is not a minor style issue; it makes the narrative claims hard to trace.\n\nI do not see a reproducible or formally verified result anywhere. My bottom line: this could be background reading for a student or a group new to AI in clinical trials, but it should not be treated as a research contribution with validated outcomes. As original research, it should be desk-rejected or sent back for a rewrite as a survey with no empirical claims. Not worth referee time in its current form.","headline":"A review-style paper whose headline results are unsupported by any artifact; the survey skeleton is fine as background reading, but the empirical claims should not survive review.","tokens_in":16892,"tokens_out":4756,"would_cite":false,"duration_ms":46437,"reading_group":"no","serious_thinker":"no","would_accept_peer_review":false},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"deepseek-v4-flash","headline":"The paper reports that an integrated pipeline of CNNs, RNNs, and transformers can cut clinical trial recruitment time by 25% and operational costs by 30% while predicting outcomes at 88–93% accuracy.","keywords":["Deep learning","Predictive modelling","Clinical trials","Precision medicine","Natural language processing","Patient stratification","Multimodal clinical data","Adverse event prediction"],"falsifier":"A reader could reconstruct an equivalent multimodal dataset from public critical-care records, genomic databases, demographic surveys, and clinical notes, run CNN, RNN/LSTM, and transformer models under the stated 70/15/15 stratified split, and check whether the reported figures (CNN 92% accuracy and 0.96 ROC-AUC, RNN 88% F1, transformer 93% precision, 25% faster recruitment, 30% lower costs) reproduce on the held-out test set. Non-reproduction within normal statistical variance would falsify the paper's quantitative central claim.","tokens_in":15972,"feed_emoji":"⚕️","tokens_out":8557,"duration_ms":77624,"temperature":0.7,"pith_summary":"The paper sets out to show that deep learning can address the biggest practical failures of clinical trials: slow recruitment, high cost, and avoidable adverse events. It reports training convolutional, recurrent, and transformer networks on a custom multimodal dataset of structured clinical records, genomic profiles, demographic data, and unstructured text, and claims the resulting pipeline reduced recruitment time by 25%, cut operational costs by 30%, and achieved predictive scores of 92% accuracy and 0.96 ROC-AUC for the CNN, 88% F1 for the RNN, and 93% precision for the transformer. The importance, if the results hold, is that trial design could become adaptive and patient-specific rather than based on population averages, which would shorten drug development timelines and make trials safer and more inclusive. The paper also surveys the surrounding literature and frames the approach as a general integration framework for precision medicine.","feed_headline":"AI models cut clinical trial recruitment time by 25%, paper reports","feed_subtitle":"A multimodal pipeline of imaging, time-series, and text models is claimed to speed enrollment and cut costs.","key_machinery":"The load-bearing mechanism is a multimodal fusion pipeline in which a CNN processes imaging data, an RNN/LSTM processes temporal clinical data, and a transformer processes unstructured text, with outputs combined through ensemble learning and dynamic risk scoring. The custom dataset, described as combining 50,000 structured patient records, 10,000 genomic records, 30,000 demographic records, and 20,000 unstructured clinical notes alongside GAN-generated synthetic data, is what carries the reported metrics; without it the architecture comparison has no empirical grounding.","core_discovery":"The paper's central claim is that an integrated deep-learning pipeline — CNNs for imaging, LSTMs for sequential vital-sign data, transformers for clinical text, plus survival analysis and dynamic risk scoring — can be trained on a fused multimodal dataset and outperform traditional statistical methods across the clinical trial workflow. The reported numbers are the evidence: 92% accuracy and 0.96 ROC-AUC for tumor detection in imaging, 88% F1 for adverse-event prediction from time series, 93% precision for extracting insights from trial protocols and notes, a 25% reduction in patient recruitment time, a 30% reduction in operational costs, and simulated trial success rates of 80% for the transformer pipeline versus 60% for traditional methods. The authors present these results as demonstrating that predictive analytics can be integrated into precision medicine to streamline trial design, monitoring, and patient-centered care.","pith_inferences":["The paper does not describe an external validation cohort or a pre-registered analysis, so the reported numbers should be read as in-sample results unless independent replication appears.","A fair comparison would require the same data, the same train/test split, and the same hyperparameters to be run by another group; until then, the 25% and 30% efficiency gains are plausibility arguments rather than measured effects.","The framework's clinical usefulness would be tested by a prospective trial in which recruitment time and adverse-event rates are measured against a concurrent control arm, not against historical baselines.","If the dataset were released with schema and preprocessing code, the three architectures could be re-benchmarked side by side, which would also let researchers weigh the transformer's higher compute cost against its precision advantage."],"forward_implications":["If the reported recruitment-speed gain translates to real trials, the 80% of studies that currently miss enrollment deadlines could be brought back on schedule.","Real-time RNN monitoring at the claimed recall level would let trial teams intervene before adverse events become serious, changing the safety monitoring workflow.","Transformer-based protocol and note analysis at 93% precision could automate much of the manual data-extraction and regulatory-documentation burden in trials.","Adaptive designs driven by these predictions would let trial sponsors re-randomize or adjust protocols as evidence accumulates, rather than waiting for trial end.","The 30% cost reduction, if real, would mean tens of millions of dollars saved per drug development program given the $2.5 billion average cost cited in the paper."],"supporting_citations":[{"why":"Supplies the real-world structured patient records that form the core training data for the trial-patient component.","marker":"[19]"},{"why":"Supplies the genomic variation data used to train treatment-personalization models.","marker":"[20]"},{"why":"Provides the GAN-based method for generating synthetic patient data to augment the limited real-world records.","marker":"[21]"},{"why":"Establishes the CNN imaging architecture whose reported accuracy and ROC-AUC anchor the results section.","marker":"[23]"},{"why":"Establishes LSTM and GRU variants for sequential clinical data, the RNN approach whose F1 score is reported.","marker":"[24]"},{"why":"Establishes transformer models for clinical text analysis, the architecture whose precision is reported at 93%.","marker":"[25]"}],"fun_headline_variants":["AI pipeline cuts trial enrollment by 25% and costs 30%","Deep learning predicts adverse events with 88% F1 score","Multimodal AI boosts trial success to 80% vs 60%","CNNs, transformers, LSTMs: AI trims trial costs 30%","AI-driven precision medicine: 92% imaging accuracy"],"cache_read_input_tokens":3200,"weakest_assumption_plain":"The load-bearing assumption is that the custom multimodal dataset described in the paper — 50,000 structured clinical records, 10,000 genomic records, 30,000 demographic records, and 20,000 unstructured text records — was actually assembled, cleaned, and used to train the models, because every reported performance and efficiency figure depends on it and the paper provides no dataset release, code, or access procedure.","fun_headline_variants_meta":{"raw":{"variants":["AI pipeline cuts trial enrollment by 25% and costs 30%","Deep learning predicts adverse events with 88% F1 score","Multimodal AI boosts trial success to 80% vs 60%","CNNs, transformers, LSTMs: AI trims trial costs 30%","AI-driven precision medicine: 92% imaging accuracy"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.000544,"raw_usage":{"total_tokens":2628,"prompt_tokens":995,"completion_tokens":1633,"prompt_tokens_details":{"cached_tokens":384},"prompt_cache_hit_tokens":384,"prompt_cache_miss_tokens":611,"completion_tokens_details":{"reasoning_tokens":1540}},"tokens_in":611,"tokens_out":1633,"duration_ms":13727,"temperature":1.0,"reasoning_tokens":1540,"cache_read_input_tokens":384,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-11T19:10:43.528048+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"A reader could reconstruct an equivalent multimodal dataset from public critical-care records, genomic databases, demographic surveys, and clinical notes, run CNN, RNN/LSTM, and transformer models under the stated 70/15/15 stratified split, and check whether the reported figures (CNN 92% accuracy and 0.96 ROC-AUC, RNN 88% F1, transformer 93% precision, 25% faster recruitment, 30% lower costs) reproduce on the held-out test set. Non-reproduction within normal statistical variance would falsify the paper's quantitative central claim.","supporting_citations":[{"cited_title":"The second machine age: Work, progress, and prosperity in a time of brilliant technologies","cited_arxiv_id":null,"evidence_quote":"Supplies the real-world structured patient records that form the core training data for the trial-patient component."},{"cited_title":"Novel Innovation Design for the Future of Health: Entrepreneurial Concepts for Patient Empowerment and Health Democratization","cited_arxiv_id":null,"evidence_quote":"Supplies the genomic variation data used to train treatment-personalization models."},{"cited_title":"AI in healthcare: Opportunities and barriers","cited_arxiv_id":null,"evidence_quote":"Provides the GAN-based method for generating synthetic patient data to augment the limited real-world records."},{"cited_title":"Generating multi -label discrete patient records using generative adversarial networks","cited_arxiv_id":null,"evidence_quote":"Establishes transformer models for clinical text analysis, the architecture whose precision is reported at 93%."}],"review_version":1}